We focus on both Asian cohorts and diseases to build up an epigenomic database that serves as a platform for novel drug and biomarker discoveries. We further develop proprietary pan-cancer epigenomic predictive models to deliver clinical insights that are complementary to genomic information today.
Our flagship clinical product, EPI-CALL™, reports epigenomic information for patients and identifies probability of response to immunotherapy. It is complementary with current Next Generation Sequencing (NGS) tests and does not require additional Formalin Fixed Paraffin Embedded (FFPE) slides. Through EPI-CALL™, we empower clinicians to make better treatment decisions for their patients.
Through our research service Signomax™, a proprietary ChIP-Seq process that is compatible with both FFPE slides and fresh frozen tissues, we advance, accelerate, and drive epigenomic research endeavours.
EPI-CALL™ – A second-generation NGS test to predict patient’s response to immunotherapy
Signomax™ – A proprietary ChIP-Seq service on both FFPE and fresh frozen tissue to analyse histone modifications
We have existing partnerships with A*STAR, Genome Institute of Singapore (GIS), Centre for Genomic Diagnostics (CGD), and Diagnostic Development Hub (DxD) to support the development and delivery of our offerings